Abstract 407P
Background
Circulating tumor DNA (ctDNA) has emerged as a promising biomarker to monitor molecular residual disease (MRD) in solid tumors after curative-intent treatment. Since imaging and plasma-derived protein biomarkers both have limited sensitivity and specificity, ctDNA could complement conventional methods to guide post-operative monitoring and treatment plans for patients. This study evaluated the clinical utility of our tumor-informed, personalized ctDNA assay to identify patients at high risk of recurrence.
Methods
This prospective multi-center study enrolled 510 patients with liver, colorectal, breast, lung, gastric and ovarian cancers who were eligible for curative-intent surgery. Genomic DNA extracted from tumor tissue and paired white blood cells was subjected to massively parallel sequencing of 150 cancer-related genes. A proprietary algorithm ranked the top somatic mutations unique to each patient, which were then used to detect ctDNA in serial plasma samples.
Results
The pre-operative detection rate of ctDNA was 91%, 97%, 62%, 65%, 57%, and 46% for colorectal, liver, lung, ovarian, high-risk breast cancer, and gastric cancer respectively; the specificity was >99% as ctDNA was not detected in the plasma from healthy donors. Our interim analysis after a 20-month follow-up demonstrated that 88% of patients with recurrence and/or metastasis (35/40) had ctDNA detected in their post-operative plasma samples. On average, such ctDNA detection was 5 months (up to 13 months) earlier than clinical diagnosis. Post-operative ctDNA was also found as an independent prognostic factor for disease-free survival in multiple types of cancer (p<0.001).
Conclusions
K-Track™ assay provides longitudinal ctDNA monitoring that showed clinical utility in predicting disease-free survival and early relapse detection in cancer patients. This simplified and cost-effective approach enables MRD monitoring to be more accessible in routine clinical practice in developing countries.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Medical Genetics Institute, Ho Chi Minh City, Vietna.
Funding
Gene Solutions JSC, Ho Chi Minh city, Vietnam.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
280P - Radium-223 for patients with metastatic castration-resistant prostate cancer with symptomatic bone metastases progressing after first-line abiraterone or enzalutamide: One institutional experience
Presenter: Keng Man Chiang
Session: Poster Display
Resources:
Abstract
281P - 10-year treatment outcome of prostate cancer patients with 3D conformal radiation: Experience of a single cancer institution in Iran
Presenter: Reyhane Bayani
Session: Poster Display
Resources:
Abstract
282P - Predictors of outcomes in patients with clinically lymph node-positive prostate cancer after definitive radiotherapy
Presenter: Jae-Sung Kim
Session: Poster Display
Resources:
Abstract
283P - Radiotherapy utilization rate and treatment patern of protate cancer at Cipto Mangunkusumo Central General Hospital (RSCM): What we learn from pre-pandemic era
Presenter: Riyan Apriantoni
Session: Poster Display
Resources:
Abstract
284TiP - CYCLONE 3: A phase III, randomized, double-blind, placebo-controlled study of abemaciclib in combination with abiraterone plus prednisone in men with high-risk metastatic hormone-sensitive prostate cancer
Presenter: Nobuaki Matsubara
Session: Poster Display
Resources:
Abstract
292P - Comparative characteristics of early cervical cancer diagnosis methods for Tashkent women
Presenter: Gulnoza Goyibova
Session: Poster Display
Resources:
Abstract
293P - Carboplatin in locally advanced cervical cancer treated with chemoradiation: An alternative to cisplatin
Presenter: Natalia Isabel Valdiviezo Lama
Session: Poster Display
Resources:
Abstract
294P - Concurrent chemoradiation with cisplatin every 3 weeks in locally advanced cervical cancer: A single arm phase II clinical trial
Presenter: Long Nguyen
Session: Poster Display
Resources:
Abstract
295P - A prospective study of dose escalated simultaneous integrated boost in node-positive cervical cancer
Presenter: Ritusha Mishra
Session: Poster Display
Resources:
Abstract
296P - Safety, efficacy, and immunogenicity of therapeutic vaccines for patients with high-grade cervical intraepithelial neoplasia (CIN 2/3) associated with human papillomavirus: A systematic review
Presenter: Caroline Amélia Gonçalves
Session: Poster Display
Resources:
Abstract